. Author manuscript; available in PMC: 2012 Oct 1.

Published in final edited form as: Clin Lymphoma Myeloma Leuk. 2011 Aug 10;11(5):421–426. doi: 10.1016/j.clml.2011.06.009

Table 2. Outcome with second line TKI and beyond (n=165).

Treatment group	Best Response	No. with Response	(%)	No. Dead	(%)	No. Transformed	(%)
Overall	CCyR	85	52	6	7	5	6
N=165	PCyR	12	7	4	33	2	17
	Min CyR	23	14	7	30	4	17
	CHR only	17/125	14	5	29	1	6
	No response	28	17	11	39	7	25
2^nd TKI	CCyR	78	57	6	8	5	6
N=136	PCyR	8	6	3	38	2	25
	Min CyR	22	16	6	27	3	14
	CHR only	13/102	14	5	38	1	8
	No response	15	11	7	47	6	40
3^rd and beyond	CCyR	7	24	0	0	0	0
n = 29	PCyR	4	14	1	25	0	0
	Min CyR	1	3	1	100	1	100
	CHR only	4/23	17	0	0	0	0
	No response	13	45	4	31	0	8